• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

byMinjee Kim
October 5, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced or preserved ejection fraction as compared to a placebo.

2. Dapagliflozin was associated with similar rates of adverse events to the placebo control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, are well-established therapies used to reduce the risk of hospitalization and cardiovascular death in patients with heart failure and a left ventricular ejection fraction (LVEF) of 40% or less. However, it is unclear if SGLT2 inhibitors are beneficial for heart failure patients with higher LVEF. The current study was a phase three multicenter trial that aimed to investigate the efficacy and safety of dapagliflozin in treating heart failure patients with LVEF great than 40%. The control group was given a placebo. Dapagliflozin recipients were at significantly lower risks of worsening heart failure and cardiovascular disease, along with reduced symptom burden, compared to placebo recipients. This benefit was observed regardless of patients’ diabetic status or LVEF. The incidence of adverse events, including death, was comparable between the dapagliflozin and placebo groups. Although, the specificity of the inclusion and exclusion criteria may impact the generalizability of the study results. The present study provided evidence to support the use of dapagliflozin in heart failure patients with high LVEF.

Click here to read the study in NEJM

In-Depth [randomized controlled trial]: The current study was a phase three multicenter, double-blind randomized controlled trial aimed at assessing the efficacy and safety of dapagliflozin in heart failure patients with LVEF greater than 40%. Patients were included if they were at least 40 years of age, had stabilized heart failure, had an LVEF higher than 40%, had evidence of structural heart disease, and had an elevated natriuretic peptide level, regardless of their type 2 diabetes mellitus status. Exclusion criteria included previous use of an SGLT2 inhibitor, impaired kidney function, history of myocardial infarction, coronary revascularization, and certain causes of heart failure. In total, 6233 patients were randomized 1:1 to receive dapagliflozin 10mg once daily or a placebo. The primary outcome was a composite of worsening heart failure, which was defined as either an unplanned hospitalization, an urgent visit for heart failure, or cardiovascular death. Secondary outcomes included the individual events within the primary outcome, symptom burden, and death from any cause. Over a median follow-up of 2.3 years, the primary outcome occurred in 513 of 3,131 dapagliflozin recipients (16.4%) and in 610 of 3,132 placebo recipients (19.5%) (Hazard Ratio [HR], 0.82; 95% Confidence Interval [CI], 0.73 to 0.92; p<0.001). Worsening heart failure occurred in 11.8% of dapagliflozin recipients and 14.5% of placebo recipients (HR, 0.79; 95% CI. 0.69 to 0.91), while cardiovascular death occurred in 7.4% and 8.3% of patients, respectively (HR, 0.88; 95% CI, 0.74 to 1.05). Notably, the impact of dapagliflozin on primary outcome remained consistent regardless of whether patients had type 2 diabetes mellitus. The incidence of adverse events was comparable between the dapagliflozin and placebo groups. Although its generalizability may be impacted by the specific inclusion and exclusion criteria, the study provided robust evidence to support the use of dapagliflozin in treating heart failure patients with preserved LVEF.

RELATED REPORTS

Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

Wellness Check: Exercise

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseaseCVdapagliflozinejection fractionheart failurehfpefHFpEF (heart failure with preserved ejection fractionLVEFSGLT-2 inhibitorssglt2 inhibitorsSGLT2i
Previous Post

The Effect of High-Polyphenol Mediterranean Diet on Visceral Adiposity

Next Post

Spirituality may improve outcomes in patients suffering from post-traumatic stress disorder

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Moderately accelerated cardiac pacing may be beneficial in patients with heart failure with preserved ejection fraction

February 5, 2023
CPAP may not decrease cardiovascular events in sleep apnea
Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

February 2, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Next Post
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Spirituality may improve outcomes in patients suffering from post-traumatic stress disorder

Roux-en-Y gastric bypass may slow progression of diabetic retinopathy

Rate of childhood vision screening decreased substantially between 2016 and 2020

#VisualAbstract: Adjuvant ibandronate does not improve survival in  postmenopausal patients with ER⁺ breast cancer

#VisualAbstract: Tislelizumab significantly improves survival outcomes in advanced or metastatic esophageal squamous cell carcinoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
  • College campus monkeypox outbreaks can be controlled with timely detection and isolation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options